Nevertheless, pharmacological inhibitors of the ERK1/2 signaling cascade are actively being explored for clinical use in RASopathies (Guilding et al., 2007; Hatzivassiliou et al., 2010; Morris et al., 2013; Nakamura et al., 2009; Zamorano et al., 2018). Here, MAPK3 is linked to RASopathy.